Kleer Celina G., Bryant Bonita R., Giordano Thomas J., Sobel Mark, Merino Maria J.
MT (ASCP).
Endocr Pathol. 2000 Summer;11(2):137-143. doi: 10.1385/ep:11:2:137.
Little is known about the genetic alterations that occur during the progression of thyroid neoplasms. To understand better the biology of thyroid tumors, we investigated several genetic loci in benign and malignant thyroid neoplasms. Forty-one thyroid tumors (6 adenomas, 16 papillary, 14 follicular, and 5 anaplastic carcinomas) were studied. Normal and tumor cells were microdissected from paraffin-embedded tissues. DNA was used for polymerase chain reaction-based loss of heterozygosity (LOH) analysis with the following markers: D1S243 (1p35-36), D1S165 (1p36) and D1S162 (1p32), TP53 (17p13), and INT-2 (11q13). Immunohistochemistry for Ki-67 was performed. The Ki-67 labeling index (LI) was the percentage of positive tumor cells. LOH at 1p was seen in 2 of 5 (40%) informative cases of anaplastic carcinoma (2 of 2 at D1S162 and 1 of 2 at D1S165) and in 2 of 11 (18%) informative cases of follicular carcinoma (2 of 7 at D1S243, 2 of 7 at D1S1654, and 1 of 6 at D1S162). One anaplastic (20%) and two follicular carcinomas (14%) had LOH in at least two of the 1p loci analyzed. None of the adenomas and papillary carcinomas had LOH at these loci. LOH at 17p and 11q13 were infrequent. Ki-67 LI was 1.4, 7, 16, and 65% in adenomas, papillary, follicular, and anaplastic carcinomas, respectively. Allelic loss at 1p may occur in aggressive types of thyroid carcinoma and may be a marker of poor prognosis. LOH at 1p may represent a late genetic event in thyroid carcinogenesis. LOH at 17p and 11q13 (MEN gene locus) is uncommon in thyroid neoplasms.
关于甲状腺肿瘤进展过程中发生的基因改变,人们了解甚少。为了更好地理解甲状腺肿瘤的生物学特性,我们研究了良性和恶性甲状腺肿瘤中的几个基因位点。研究了41例甲状腺肿瘤(6例腺瘤、16例乳头状癌、14例滤泡状癌和5例未分化癌)。从石蜡包埋组织中显微切割正常细胞和肿瘤细胞。使用DNA进行基于聚合酶链反应的杂合性缺失(LOH)分析,所用标记如下:D1S243(1p35 - 36)、D1S165(1p36)和D1S162(1p32)、TP53(17p13)以及INT - 2(11q13)。进行了Ki - 67的免疫组织化学检测。Ki - 67标记指数(LI)是阳性肿瘤细胞的百分比。在5例信息充分的未分化癌病例中有2例(40%)出现1p杂合性缺失(D1S162处2例,D1S165处1例),在11例信息充分的滤泡状癌病例中有2例(18%)出现1p杂合性缺失(D1S243处7例中有2例,D1S1654处7例中有2例,D1S162处6例中有1例)。1例未分化癌(20%)和2例滤泡状癌(14%)在至少两个分析的1p位点出现杂合性缺失。腺瘤和乳头状癌在这些位点均未出现杂合性缺失。17p和11q13处的杂合性缺失很少见。腺瘤、乳头状癌、滤泡状癌和未分化癌的Ki - 67 LI分别为1.4%、7%、16%和65%。1p处的等位基因缺失可能发生在侵袭性甲状腺癌类型中,可能是预后不良的一个标志物。1p处的杂合性缺失可能代表甲状腺癌发生过程中的一个晚期基因事件。17p和11q13(MEN基因位点)处的杂合性缺失在甲状腺肿瘤中不常见。